Search

The WHO Mental Health Gap Action Programme (mhGAP) guideline update reflects 15 years of investment in reducing the treatment gap and scaling up care for people with mental, neurological, and substance use (MNS) conditions. It was produced by a guideline development group and steering group, with support from topic experts, using quantitative and qualitative evidence and a systematic review of use of mhGAP. 90 recommendations from the 2015 guideline update were validated and endorsed for use in their current format. These are joined by 30 revised recommendations and 18 new recommendations, including a new module on anxiety. Psychological interventions are emphasised as treatments and digitally delivered interventions feature across many modules, as well as updated recommendations for psychotropic medicines. Research gaps identified include the need for evidence from low-resource settings and on the views of people with lived experience of MNS conditions. The revised recommendations ensure that mhGAP continues to offer high-quality, timely, transparent, and evidence-based guidance to support non-specialist health workers in low-income and middle-income countries in providing care to individuals with MNS conditions.

Researchers preparing systematic review articles frequently face rejection by journal editors and peer-reviewers, leading invariably to time wastage in the rejectionresubmission cycle. In addition to undertaking the review work, authors need to understand the manuscript assessment mechanisms and the publication process within medical journals. Prospective registration boosts the authenticity of the review. The abstract is the most important part of the manuscript as it will make the first impression. The article structure is normally pre-determined according to the journal´s instructions, and compliance with writing checklists is mandatory. It is a good idea to deploy checklist items in writing up from the beginning. Introduction and discussion sections may not be hard to draft if one follows a structured approach. This article will help familiarize authors with unwritten rules about the publication of reviews, giving writing tips to increase the probability of the manuscript being accepted on the first submission., Los investigadores que preparan artículos de revisión sistemática se enfrentan con frecuencia al rechazo de los editores y revisores de revistas médicas, lo que conlleva indudablemente a una pérdida de tiempo en el proceso de presentación-rechazo y nueva presentación a otra revista. Además de emprender el trabajo de revisión, los autores deben conocer los mecanismos de evaluación de los manuscritos y el proceso de publicación en revistas médicas. Un registro prospectivo de la revisión sistemática potencia la autenticidad de la misma. Por otra parte, el resumen es la parte más importante del manuscrito, ya que causará la primera impresión. La estructura del artículo suele estar predeterminada de acuerdo con las instrucciones de la revista, y el cumplimiento de las listas de comprobación de la redacción proporcionadas por cada revista es obligatorio. Por lo tanto, es una buena idea basarse en estos elementos de la lista de comprobación desde el principio. Las secciones de introducción y discusión no deberían ser difíciles de redactar si se sigue un enfoque estructurado. El presente artículo ayudará a los autores a familiarizarse con las normas no escritas sobre la publicación de revisiones, dando consejos de redacción para aumentar la probabilidad de que el manuscrito sea aceptado en el primer envío.

The aim of present study was waste water treatment via advanced oxidation process (AOP). Wet chemical precipitation method was used to prepare silver nanoparticles (Ag NPs). The Ag NPs were employed for photo catalytic degradation of Congo red (CR) dye in aqueous medium. The scanning electron microscopy (SEM) investigation shows agglomerated form of Ag NPs. The average sizes of agglomerations are below 600 nm. Energy dispersive X-rays spectroscopy (EDX) and ultraviolet light visible spectroscopy (UV/Vis) also established the formation of Ag NPs. The photo-degradation study reveals that Ag NPs degraded by 73% of CR dye in 480 min. Catalytic dosage study shows the dye degradation was increased vice versa as increased the amount of Ag NPs and then almost level off after 0.025 g of catalyst. In pH study it was observed that degradation of CR dye increased as pH increased. The recovered catalyst study also significantly degraded the CR dye.

Background: E-mental health is an established mode of delivering treatment for common mental disorders in many high income countries. However, evidence of its effectiveness in lower income countries is lacking. This mixed methods study presents lessons learned and preliminary data on the feasibility of a minimally guided e-mental health intervention in Lebanon. The aim was to pilot test Step-by-Step, a WHO guided e-mental health intervention, and research methods prior to future, controlled testing. Methods: Participants were recruited using social media and advertisements in primary care clinics. Participants completed baseline and post-intervention questionnaires on depression symptoms (primary outcome, PHQ-8), anxiety symptoms, well-being, disability and self-perceived problem severity, and a client satisfaction questionnaire. In addition, seven completers, four drop-outs, 11 study staff, and four clinic managers were interviewed with responses thematically analyzed. Website analytics were used to understand participant behavior when using the website. Results: A total of 129 participants signed up via the Step-by-Step website. Seventy-four participants started session 1 after completing pre-test questionnaires and 26 completed both baseline and post-intervention data. Among those who completed post-assessments, depression symptoms improved (PHQ-8 scores (t=5.62, p < 0.001 two-tailed, df = 25). Wilcoxon signed ranks tests showed a significant difference between baseline and post-Step-by-Step scores on all secondary outcome measures. Client satisfaction data was positive. Interview responses suggested that the intervention could be made more appropriate for younger, single people, more motivating, and easier to use. Those who utilized the support element of the intervention were happy with their relationship with the non-specialist support person (e-helper), though some participants would have preferred specialist support. E-helpers would have liked more training

Background Technology development to enable the culture of human prostate cancer (PCa) progenitor cells is required for the identification of new, potentially curative therapies for PCa. Objective We established and characterized patient-derived conditionally reprogrammed cells (CRCs) to assess their biological properties and to apply these to test the efficacies of drugs. Design, setting, and participants CRCs were established from seven patient samples with disease ranging from primary PCa to advanced castration-resistant PCa (CRPC). The CRCs were characterized by genomic, transcriptomic, protein expression, and drug profiling. Outcome measurements and statistical analysis The phenotypic quantification of the CRCs was done based on immunostaining followed by image analysis with Advanced Cell Classifier using Random Forest supervised machine learning. Copy number aberrations (CNAs) were called from whole-exome sequencing and transcriptomics using in-house pipelines. Dose-response measurements were used to generate multiparameter drug sensitivity scores using R-statistical language. Results and limitations We generated six benign CRC cultures which all had an androgen receptor-negative, basal/transit-amplifying phenotype with few CNAs. In three-dimensional cell culture, these cells could re-express the androgen receptor. The CRCs from a CRPC patient (HUB.5) displayed multiple CNAs, many of which were shared with the parental tumor. We carried out high-throughput drug-response studies with 306 emerging and clinical cancer drugs. Using the benign CRCs as controls, we identified the Bcl-2 family inhibitor navitoclax as the most potent cancer-specific drug for the CRCs from a CRPC patient. Other drug efficacies included taxanes, mepacrine, and retinoids. Conclusions Comprehensive cancer pharmacopeia-wide drug testing of CRCs from a CRPC patient highlighted both known and novel drug sensitivities in PCa, including navitoclax, which is currently being tested in clinical t

Human Adenovirus type 5 encodes two short RNA polymerase III transcripts, the virus-associated (VA) RNAI and VA RNAII, which can adopt stable hairpin structures that resemble micro-RNA precursors. The terminal stems of the VA RNAs are processed into small RNAs (mivaRNAs) that are incorporated into RISC. It has been reported that VA RNAI has two transcription initiation sites, which produce two VA RNAI species; a major species, VA RNAI(G), which accounts for 75% of the VA RNAI pool, and a minor species, VA RNAI(A), which initiates transcription three nucleotides upstream compared to VA RNAI(G). We show that this 5′-heterogeneity results in a dramatic difference in RISC assembly. Thus, both VA RNAI(G) and VA RNAI(A) are processed by Dicer at the same position in the terminal stem generating the same 3′-strand mivaRNA. This mivaRNA is incorporated into RISC with 200-fold higher efficiency compared to the 5′-strand of mivaRNAI. Of the small number of 5′-strands used in RISC assembly only VA RNAI(A) generated active RISC complexes. We also show that the 3′-strand of mivaRNAI, although being the preferred substrate for RISC assembly, generates unstable RISC complexes with a low in vitro cleavage activity, only around 2% compared to RISC assembled on the VA RNAI(A) 5′-strand.

Thesis (Ph.D.)--Massachusetts Institute of Technology, Alfred P. Sloan School of Management, 1981., MICROFICHE COPY AVAILABLE IN ARCHIVES AND DEWEY., Bibliography: leaves 410-416., by Khalid Saeed., Ph.D.

by Khalid Saeed., Thesis (Ph.D.)--Massachusetts Institute of Technology, Alfred P. Sloan School of Management, 1981., MICROFICHE COPY AVAILABLE IN ARCHIVES AND DEWEY., Bibliography: leaves 410-416.